Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Maria Soler Nunez appointed as Head, Group Operations: https://mailing-ircockpit.eqs.com/crm-mailing/5b71ace0-ea7c-11e8-902f-2c44fd856d8c/da75bbed-f3bc-4a1d-9875-d27419257884/44372190-575f-48fc-882c-357bfd2721ce/MSN.jpg
Maria Soler Nunez appointed as Head, Group Operations
Maria Soler Nunez appointed as Head, Group Operations
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis


Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health

Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company

VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Medicines Agency’s (EMA) CHMP has recommended

Vifor Pharma announces changes to its Executive Committee: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma announces changes to its Executive Committee


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced changes to its Executive Committee as current members Lee Heeson, President International, and

VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan


Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing

GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID


GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005966/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor

Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines


Regulatory News:



Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1 : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1


Regulatory News:



Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient

Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma


Regulatory News:



Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain

Vifor Pharma to revise DIAMOND study, readout expected in H2 2021: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021


Regulatory News:



Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in

93rd Vifor Pharma Group Annual General Meeting: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
93rd Vifor Pharma Group Annual General Meeting


Regulatory News:



At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19

VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China


Regulatory News:



Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21)

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/



Vifor Pharma and Angion Biomedica Corp. (NASDAQ

First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment


Regulatory News:



Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005652/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors


Regulatory News:



Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.



Åsa Riisberg, a

Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1


Regulatory News:



Vifor Pharma Group reported stable net sales and a continued strong increase in profitability in 2020, despite challenges to patient access from COVID-19 and the impact of a much

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member


Regulatory News:



Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.



Jacques

Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality


Regulatory News:



Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron